Modern Australian
Men's Weekly

.

Poredeen Appoints ICB as Exclusive Named Patient Program Manager for HMTM# in Hong Kong and Macau

“Making TauRx’s groundbreaking drug HMTM# accessible to patients with Alzheimer's Disease under Named Patient Program”

HONG KONG SAR / SINGAPORE - Media OutReach Neswire - 18 January 2024 - ICB Medical Ltd ("ICB"), a member of the Immuno Cure BioTech Group ("Immuno Cure"), is appointed as the exclusive Named Patient Program ("NPP") Manager, for TauRx's groundbreaking drug, Hydromethylthionine Mesylate ("HMTM#"), in Hong Kong SAR and Macau SAR ("Territories") by Poredeen Pte Ltd ("Poredeen"), a wholly owned subsidiary within the TauRx Pharmaceuticals Ltd group of companies ("TauRx").

Immuno Cure is a biotechnology group based in Hong Kong Science Park also committed to advancing healthcare solutions.

Poredeen Appoints ICB as Exclusive Named Patient Program Manager for HMTM# in Hong Kong and Macau
Poredeen Appoints ICB as Exclusive Named Patient Program Manager for HMTM# in Hong Kong and Macau

Poredeen grants ICB the exclusive rights to manage the importation and logistics for the HMTM# tablets under the NPP such that qualified prescribing doctors in the Territories can request HMTM# on behalf of eligible patients. HMTM# is currently undergoing clinical evaluation for its potential use in managing Mild Cognitive Impairment ("MCI"), Alzheimer's Disease ("AD") and behavioural-variant Fronto Temporal Dementia ("bvFTD"). It is not registered for commercial sale in the Territories. This NPP marks a significant milestone in the parties' joint mission to combat some of the world's most challenging and prevalent neurodegenerative diseases in the Territories.

Promising results are observed in LUCIDITY, TauRx's third and latest global Phase 3 clinical trial of HMTM#, offering hope to many patients and their families. LUCIDITY comprised a 12-month double-blind controlled Phase 3 clinical trial followed by a 12-month period in which all participants received HMTM# at 16 mg/day as a monotherapy. The trial investigated changes in various clinical and biomarker outcomes comparing HMTM# 16 mg/day with methylthioninium chloride ("MTC") given 4 mg twice weekly as a control over the first 12 months.

The safety profile seen in LUCIDITY remains positive and consistent with earlier published HMTM# trials data. There were no treatment-related serious adverse events or evidence of amyloid-related imaging abnormalities ("ARIA") in LUCIDITY. The LUCIDITY trial is now complete and TauRx is preparing peer-reviewed publications to report the full 24-month data.

Alzheimer's Disease is one of the leading causes of death throughout the world and one of the most important public health issues to be addressed globally. TauRx will contribute to addressing this unmet need with data from LUCIDITY. In the United Kingdom, TauRx is actively pursuing approval from the Medicines and Healthcare products Regulatory Agency ("MHRA UK") through the Innovative Licensing and Access Pathway ("ILAP"). TauRx was granted an Innovation Passport in May 2022, marking the first stage of the approval process, indicating MHRA UK's recognition of the potential importance of this medication for Alzheimer's Disease.

TauRx is also submitting the HMTM# results from LUCIDITY and earlier trials for regulatory approval in the USA. TauRx and Poredeen will be meeting and submitting data packages to other drug regulators in more territories, including the People's Republic of China ("China"), soon.

"This appointment reflects our unwavering dedication to improving the lives of those impacted by AD," stated TauRx's Managing Director, Dr SENG Shay Way, "We are delighted to appoint ICB as NPP Manager so that doctors may request this groundbreaking product for their eligible patients in need. Through this appointment, we aim to make a substantial and positive difference in the fight against AD thereby enhancing the quality of life for the patients, their families and caregivers."

"We focus on upholding the highest quality standards and compliance with regulatory guidelines," Poredeen's Executive Director, Dr LOH Yin Sze echoed, "where patient safety and well-being are of paramount importance, and our dedicated team will collaborate closely with ICB to provide ongoing support and education regarding this groundbreaking drug."

Securing this appointment not only expands Immuno Cure's position as a leading player in the biotech sector into pharmaceutical services but also showcases ICB's commitment to addressing critical unmet medical needs of AD patients through the launching of the NPP for prescribing doctors' immediate access to TauRx's HMTM#.

"We are delighted to be appointed the exclusive NPP Manager by Poredeen. Through our close relationship with healthcare institutions and practitioners, ICB will ensure the efficient and timely accessibility of HMTM# to the prescribing doctors and their patients," ICB's Chairman, Dr Percy Cheng said. "ICB will work closely with healthcare institutions, professionals, patient advocacy groups, and regulatory authorities to ensure the swift, safe and responsible availability of this groundbreaking treatment to eligible patients in need in Hong Kong and Macau."

TauRx, Poredeen and ICB are strategically aligned and committed to propel forward in their mission to transform the landscape of neurodegenerative disease treatment and make a profound improvement to the lives of those affected by MCI, AD and bvFTD and their families.

HMTM# is an investigational drug which has not received approval for any indications in the Territories, and its efficacy and safety have not yet been evaluated for registration purposes.

Disclaimer: This press release contains commercial information. It does not constitute any medical advice, and should not be treated as such. Any questions about any medical matter should be directed to medical practitioners or other professional healthcare provider.


Hashtag: #ICB #TauRx

The issuer is solely responsible for the content of this announcement.

About TauRx and Poredeen:

The TauRx group of companies was established in 2002 in Singapore, continuing a collaboration with the University of Aberdeen, with primary research facilities and operations based in Aberdeen, UK. The company has dedicated the past two decades to developing treatments and diagnostics for Alzheimer's and other neurodegenerative diseases due to protein aggregation pathology.

TauRx is dedicated to research in neurodegenerative diseases and is a leader in AD research, with a mission to discover, develop and commercialise innovative products for the diagnosis, treatment and cure of neurodegenerative diseases caused by toxic protein aggregations.

Poredeen is a wholly-owned subsidiary of TauRx that holds exclusive rights for China, including Hong Kong SAR and Macau SAR.

For more details, please click here:

About LUCIDITY:

LUCIDITY is the only late-stage clinical trial specifically targeting the tau pathology of Alzheimer's Disease.

Aggregation of abnormal tau protein is one of the hallmark pathologies. Tau aggregation and the subsequent formation of tau tangles disrupt neuronal function, a process that begins many years before symptoms of dementia are seen. Tau pathology correlates strongly with Alzheimer's severity and the clinical decline (loss of memory and ability to care for one's self) commonly seen in people with Alzheimer's.

The LUCIDITY trial is designed to confirm the efficacy and safety of HMTM* (Hydromethylthionine Mesylate) to support regulatory submission as the first disease modifying tau targeting treatment for Mild Cognitive Impairment and Mild-to-Moderate stages of Alzheimer's disease.

*Previously also abbreviated to LMTM and LMTX.

For more details, please click:

About Immuno Cure and ICB:

Immuno Cure is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of immunotherapies for cancers, inflammatory and infectious diseases based on its patented PD-1-enhanced DNA vaccine and Anti-Δ42PD1 Antibody platforms; with two DNA vaccine candidates currently in clinical trials. ICB is a member of the Immuno Cure Group, dedicated to providing professional services with innovative pharmaceutical therapies.

For more details, please click here:

Powering Shepparton’s Businesses: Expert Commercial Electrical Services You Can Count On

When it comes to running a successful business, having reliable, compliant, and efficient electrical systems is non-negotiable. From small retail ou...

Maximise Efficiency: Cleaner Solar Panels for Optimal Performance

Solar panels are a smart investment in energy efficiency, sustainability, and long-term savings—especially here in Cairns, where the tropical sun ...

7 Common Air Conditioner Issues in Melbourne – And How to Fix Them

Image by freepik Living in Melbourne, we all know how unpredictable the weather can be. One moment it’s cold and windy, the next it’s a scorchin...

Powering Palm QLD with Reliable Electrical Solutions

Image by pvproductions on Freepik When it comes to finding a trustworthy electrician Palm QLD locals can count on, the team at East Coast Sparkies s...

The Smart Way to Grow Online: SEO Management Sydney Businesses Can Rely On

If you’re a Sydney-based business owner, you already know the digital space is crowded. But with the right strategy, you don’t need to shout the...

What Your Car Says About You: The Personality Behind the Vehicle

You can tell a lot about someone by the car they drive—or at least, that’s what people think. True Blue Mobile Mechanics reckon the car says a l...

The Confidence Curve: Why Boudoir Photography Is the Empowerment Trend You Didn’t Know You Needed

Boudoir photography has been quietly taking over social feeds, Pinterest boards, and personal milestones—and for good reason. It’s not just abou...

Understanding Level 2 Electricians: Why Sydney Residents Need Licenced Experts for Complex Electrical Work

When it comes to electrical work around the home or business, not all electricians are created equal. In Sydney, particularly when you're dealing wi...

Retirement Anchored in Model Boat Building for Waterford’s Doug Unsold

WATERFORD — When Doug Unsold sees his ship come in, it’s usually one he’s crafted with his own hands. The 67-year-old retiree from Waterford ...

The Science Behind Alarm Clocks and Your Circadian Rhythm

Waking up on time isn’t just about setting an alarm—it’s about working with your body, not against it. At the heart of every restful night and...

How to Use Plants to Create a Calming Atmosphere in Your Home

In today’s fast-paced world, cultivating a calm, soothing environment at home has never been more important. Whether you live in a busy urban apar...

How Maths Tutoring Can Help Students Master Maths

Mathematics can be a daunting subject for many students, often causing stress and frustration. However, maths tutoring has proven to be an effective...

Refurbished iPads Are Better Than New Ones (Here's Why)

Image by rawpixel.com on Freepik Apple's refurbished iPad program has quietly become one of the best deals in tech. While everyone obsesses over the ...

Your Guide to Finding the Right GP: What Perth City Doctors Offer Today

Choosing a General Practitioner (GP) is one of the most important health decisions you’ll make. Luckily, Perth’s vibrant CBD now hosts a new ge...

Why Every Mining Operation Needs a Robust Safety Management System

Mining is one of the backbones of the Australian economy, particularly in Western Australia. Back in 2019-20, mining contributed 10.4% of Australia...

Australian Classic Literature Enjoys Resurgence

Welcome back to the good old days of storytelling! As the modern world becomes increasingly more demanding, returning to childhood favourites offers...

How to Choose the Right Lawyers in Sydney for Your Situation

When faced with a legal issue, selecting the right legal representation can make all the difference. Whether you're dealing with a personal injury, ...

Building a Governance Model for Headless Content Management at Scale

Image by pch.vector on Freepik There's never been a better time to implement a headless content management system (CMS) to gain the flexibility and ...